Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | EEF2K | O00418 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2746042 | 1.00 | PTGS2 (0.52) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL8991929 | 0.93 | PTGS2 (0.45) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL8894724 | 0.93 | PTGS2 (0.45) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL6430738 | 0.91 | PTGS2 (0.45) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL6430736 | 0.91 | PTGS2 (0.45) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL8933401 | 0.89 | PTGS2 (0.49) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL8895650 | 0.89 | PTGS2 (0.49) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL7700018 | 0.88 | PTGS2 (0.48) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL7700021 | 0.88 | PTGS2 (0.48) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL8532127 | 0.85 | PTGS2 (0.46) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054390-A1 | Use of haptoglobin genotyping in diagnosis and treatment of intraplaque hemorrhage resulting from plaque rupture | LEVY ANDREW | 2009-02-26 | — | — | US | claimed |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | claimed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1996022772-A1 | METHOD FOR TREATING MULTIPLE SCLEROSIS | ELI LILLY AND COMPANY (US) | 1996-08-01 | — | — | WO | claimed |
| EP-0722729-A2 | Aryl-substituted rhodanines for treating multiple sclerosis | ELI LILLY AND COMPANY (US) | 1996-07-24 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| US-5356917-A | Antiischemic, antiinflammatory, antiarthritic agents, treat-ment of dystrophic mammals | ELI LILLY AND COMPANY (US) | 1994-10-18 | — | — | US | claimed |
| US-5158966-A | Aryl-substituted rhodanine derivatives | THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1992-10-27 | — | — | US | claimed |
| WO-2014176460-A1 | METHODS OF TREATING BEHAVIORIAL AND/OR MENTAL DISORDERS | CHAU DAVID T (US) | 2014-10-30 | — | — | WO | disclosed |
| WO-2013119825-A1 | MODULATORS OF TOUSLED KINASE IN CELLULAR PROCESSES | DE BENEDETTI ARRIGO (US) | 2013-08-15 | — | — | WO | disclosed |
| US-8486922-B2 | Composition | CHEN CHIEN-HUNG (TW) | 2013-07-16 | — | — | US | disclosed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | disclosed |
| US-8178516-B2 | Composition of 4-guanidinobenzoic acid HCl, a co-agent suitable for systemic administration solely via the oral route, antioxidants, vitamins, metabolites | Sylvan Labs, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-5216002-A | Using benzyl substituted rhodanine derivatives as pure enantiomeric form | ELI LILLY AND COMPANY (US) | 1993-06-01 | — | — | US | disclosed |
| US-5158966-A | Aryl-substituted rhodanine derivatives | THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1992-10-27 | — | — | US | disclosed |
| EP-0500337-A1 | Composition containing aryl-substituted rhodanine derivatives for the treatment of type I diabetes | UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1992-08-26 | — | — | EP | disclosed |
| EP-0434394-A2 | Compounds for treating inflammatory bowel disease | ELI LILLY AND COMPANY (US) | 1991-06-26 | — | — | EP | disclosed |
| EP-0391644-A2 | Aryl-substituted rhodanine derivatives | ELI LILLY AND COMPANY (US) | 1990-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054390-A1 | Use of haptoglobin genotyping in diagnosis and treatment of intraplaque hemorrhage resulting from plaque rupture | APOB, PPHLN1, SERPINC1 | PTGS2 127/4885PTGS1 101/4885CYP1A2 1556/4885 |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | PTGS2 33/4885PTGS1 11/4885CYP1A2 338/4885 |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | PTGS2 30/4885PTGS1 8/4885CYP1A2 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.